NO20076067L - Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne - Google Patents

Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne

Info

Publication number
NO20076067L
NO20076067L NO20076067A NO20076067A NO20076067L NO 20076067 L NO20076067 L NO 20076067L NO 20076067 A NO20076067 A NO 20076067A NO 20076067 A NO20076067 A NO 20076067A NO 20076067 L NO20076067 L NO 20076067L
Authority
NO
Norway
Prior art keywords
cyanoquinolines
methods
substituted
intermediates
synthesis
Prior art date
Application number
NO20076067A
Other languages
English (en)
Inventor
Warren Chew
Gloria Karen Cheal
Jacqueline Francesca Lunetta
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37037465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076067(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20076067L publication Critical patent/NO20076067L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)

Abstract

Oppfinnelsen angår metoder for fremstilling av substituerte 3-cyanokinoliner, omfattende forbindelser i henhold til følgende formel: Metodene er egnet for fremstilling i stor skala, unngår anvendelse av kromatografiske separeringer, og gir et stabilt produkt med høy renhet mer effektivt enn tidligere teknikk.
NO20076067A 2005-05-25 2007-11-26 Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne NO20076067L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68439105P 2005-05-25 2005-05-25
PCT/US2006/016215 WO2006127207A1 (en) 2005-05-25 2006-04-28 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof

Publications (1)

Publication Number Publication Date
NO20076067L true NO20076067L (no) 2007-12-21

Family

ID=37037465

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076067A NO20076067L (no) 2005-05-25 2007-11-26 Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne

Country Status (19)

Country Link
US (1) US20060270668A1 (no)
EP (1) EP1883631A1 (no)
JP (1) JP2008545688A (no)
KR (1) KR20080016671A (no)
CN (1) CN101203494A (no)
AR (1) AR053872A1 (no)
AU (1) AU2006249600A1 (no)
BR (1) BRPI0610147A2 (no)
CA (1) CA2609186A1 (no)
CR (1) CR9544A (no)
GT (1) GT200600213A (no)
IL (1) IL187532A0 (no)
NO (1) NO20076067L (no)
PA (1) PA8676201A1 (no)
PE (1) PE20061417A1 (no)
RU (1) RU2007143161A (no)
TW (1) TW200716557A (no)
WO (1) WO2006127207A1 (no)
ZA (1) ZA200710148B (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
AU2013202912B2 (en) * 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
AU2013203571B2 (en) * 2007-10-17 2016-06-16 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2016225895B2 (en) * 2007-10-17 2018-02-08 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
JP2009215259A (ja) * 2008-03-12 2009-09-24 Ube Ind Ltd ３−ハロゲノ−４−ヒドロカルビルオキシニトロベンゼン化合物の製造方法
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN101723854A (zh) * 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2680850B1 (en) * 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102718749A (zh) * 2011-03-30 2012-10-10 北京德众万全药物技术开发有限公司 抗肿瘤药物诺那替尼的制备方法
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
AU2013299859B2 (en) 2012-08-06 2017-06-15 Firmenich Incorporated Sweet flavor modifier
CN103588755B (zh) * 2012-08-17 2016-06-22 正大天晴药业集团股份有限公司 Neratinib的制备方法
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103265530A (zh) * 2013-06-14 2013-08-28 苏州明锐医药科技有限公司 来那替尼的制备方法
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN105367552A (zh) 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
CN105461689B (zh) * 2015-05-19 2018-12-04 上海麦步医药科技有限公司 一种表皮生长因子受体(egfr)抑制剂来那替尼的新型制备方法
CN105085485B (zh) * 2015-08-21 2017-08-29 哈尔滨珍宝制药有限公司 一种来那替尼的制备方法
CN105330646B (zh) * 2015-12-04 2019-05-24 上海勋和医药科技有限公司 一种抗肿瘤药马来酸来那替尼的制备方法
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN105949176B (zh) * 2016-06-24 2018-10-26 浙江海正药业股份有限公司 一种来那替尼的纯化方法
US20200308141A1 (en) 2016-06-27 2020-10-01 Pliva Hrvatska D.O.O. Solid state forms of neratinib and salts thereof
CN106220560A (zh) * 2016-07-27 2016-12-14 华侨大学 一种多取代喹啉衍生物的制备方法
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN111344280B (zh) * 2017-11-20 2022-08-12 苏州韬略生物科技股份有限公司 (e)-n-(3-氰基-7-乙氧基-4-((4-苯氧基苯基)氨基)喹啉-6-基)-4-(二甲基氨基) 丁-2-烯酰胺马来酸盐及晶型
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN108373467A (zh) * 2018-04-27 2018-08-07 江苏创诺制药有限公司 来那替尼游离碱晶型及制备方法
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
CN109320686B (zh) * 2018-08-29 2021-06-08 华南理工大学 一种聚异脲类聚合物及其制备方法和应用
CN112679473B (zh) * 2019-10-18 2024-03-05 四川科伦药物研究院有限公司 来那替尼中间体晶体、制备方法及其用途
CN111875539B (zh) * 2020-07-15 2022-06-21 苏中药业集团股份有限公司 一种egfr类分子靶向抗肿瘤药物的制备方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111848582A (zh) * 2020-08-19 2020-10-30 重庆医科大学 制备表皮生长因子受体抑制剂来那替尼有关物质的方法
KR102713340B1 (ko) * 2022-11-08 2024-10-02 경희대학교 산학협력단 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CZ303899B6 (cs) * 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP1472213B1 (en) * 2002-02-05 2010-06-09 Wyeth a Corporation of the State of Delaware Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
AU2004267061A1 (en) * 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
EP1670473A1 (en) * 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituted quinolines as protein tyrosine kinase enzyme inhibitors
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN1930128A (zh) * 2004-01-16 2007-03-14 惠氏公司 受体酪氨酸激酶抑制剂的喹啉中间体及其合成

Also Published As

Publication number Publication date
ZA200710148B (en) 2008-09-25
AR053872A1 (es) 2007-05-23
JP2008545688A (ja) 2008-12-18
BRPI0610147A2 (pt) 2010-06-01
US20060270668A1 (en) 2006-11-30
PA8676201A1 (es) 2009-03-31
TW200716557A (en) 2007-05-01
CN101203494A (zh) 2008-06-18
AU2006249600A1 (en) 2006-11-30
WO2006127207A1 (en) 2006-11-30
EP1883631A1 (en) 2008-02-06
CA2609186A1 (en) 2006-11-30
IL187532A0 (en) 2008-03-20
PE20061417A1 (es) 2007-01-20
CR9544A (es) 2008-03-07
KR20080016671A (ko) 2008-02-21
RU2007143161A (ru) 2009-07-10
GT200600213A (es) 2007-01-12

Similar Documents

Publication Publication Date Title
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MY153915A (en) Organic compounds
EA200870116A1 (ru) Бициклические гетероарильные соединения
MA32508B1 (fr) Composes organiques
NO20073182L (no) Indazol-karboksamidforbindelser
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
TW200640924A (en) VEGF-R2 inhibitors and methods
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
TW200740844A (en) Novel MAdCAM antibodies
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
NO20065052L (no) Krystallinsk polymorf av et bazedoksifenacetat
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
GB0508318D0 (en) Organic compounds
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application